Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape.

Autor:	Kinoshita S; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.; Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan., Cortright K; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan., Crawford A; Virtual Mental Health and Outreach, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Mizuno Y; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Yoshida K; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.; Pharmacogenetics Research Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada., Hilty D; Mental Health, Northern California Veterans Administration Health Care System, Mather, CA, USA.; Department of Psychiatry & Behavioral Sciences, University of California Davis, Sacramento, CA, USA., Guinart D; Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA., Torous J; Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Correll CU; Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany., Castle DJ; Department of Psychiatry, University of Melbourne, Parkville, Australia.; Department of Psychiatry, St Vincent's Hospital, Fitzroy, Australia., Rocha D; Psychoses Unit, Ambulatório de Psiquiatria Dra. Jandira Masur, São Paulo-SP, Brazil., Yang Y; Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau Special Administrative Region, China., Xiang YT; Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau Special Administrative Region, China., Kølbæk P; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Dines D; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark., ElShami M; Shezlong, Inc., Cairo, Egypt., Jain P; Department of Psychiatry, Grant Government Medical College, Mumbai, India., Kallivayalil R; Department of Psychiatry, Pushpagiri Institute of Medical Sciences, Tiruvalla, India., Solmi M; Department of Neuroscience, University of Padua, Padua, Italy.; Padova Neuroscience Center (PNC), University of Padua, Padua, Italy., Favaro A; Department of Neuroscience, University of Padua, Padua, Italy.; Padova Neuroscience Center (PNC), University of Padua, Padua, Italy., Veronese N; Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy., Seedat S; Department of Psychiatry, Stellenbosch University, Cape Town, South Africa., Shin S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Salazar de Pablo G; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, Madrid, Spain.; Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Chang CH; An Nan Hospital, China Medical University, Tainan, Taiwan., Su KP; An Nan Hospital, China Medical University, Tainan, Taiwan.; College of Medicine, China Medical University, Taichung, Taiwan., Karas H; Department of Psychology, Istanbul Gelişim University, Istanbul, Turkey., Kane JM; Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA., Yellowlees P; Department of Psychiatry, University of California Davis, Sacramento, CA, USA., Kishimoto T; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.; Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Jazyk:	angličtina
Zdroj:	Psychological medicine [Psychol Med] 2022 Oct; Vol. 52 (13), pp. 2606-2613. Date of Electronic Publication: 2020 Nov 27.
DOI:	10.1017/S0033291720004584
Abstrakt:	Background: During the COVID-19 pandemic, the use of telemedicine as a way to reduce COVID-19 infections was noted and consequently deregulated. However, the degree of telemedicine regulation varies from country to country, which may alter the widespread use of telemedicine. This study aimed to clarify the telepsychiatry regulations for each collaborating country/region before and during the COVID-19 pandemic. Methods: We used snowball sampling within a global network of international telepsychiatry experts. Thirty collaborators from 17 different countries/regions responded to a questionnaire on barriers to the use and implementation of telepsychiatric care, including policy factors such as regulations and reimbursement at the end of 2019 and as of May 2020. Results: Thirteen of 17 regions reported a relaxation of regulations due to the pandemic; consequently, all regions surveyed stated that telepsychiatry was now possible within their public healthcare systems. In some regions, restrictions on prescription medications allowed via telepsychiatry were eased, but in 11 of the 17 regions, there were still restrictions on prescribing medications via telepsychiatry. Lower insurance reimbursement amounts for telepsychiatry consultations v. in-person consultations were reevaluated in four regions, and consequently, in 15 regions telepsychiatry services were reimbursed at the same rate (or higher) than in-person consultations during the COVID-19 pandemic. Conclusions: Our results confirm that, due to COVID-19, the majority of countries surveyed are altering telemedicine regulations that had previously restricted the spread of telemedicine. These findings provide information that could guide future policy and regulatory decisions, which facilitate greater scale and spread of telepsychiatry globally.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu